Hammer Asset Management’s Biogen BIIB Stock Holding History

Hammer Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-824	Closed	-$261K	–	45
2020 Q1	$261K	Sell	824 -5,033	-86%	-$1.53M	0.82%	43
2019 Q4	$1.74M	Sell	5,857 -1,060	-15%	-$294K	1.31%	40
2019 Q3	$1.61M	Sell	6,917 -30	-0.4%	-$6.99K	1.28%	40
2019 Q2	$1.63M	Buy	+6,947	New	+$1.6M	1.34%	40
2018 Q3	–	Sell	-6,987	Closed	-$2.03M	–	48
2018 Q2	$2.03M	Buy	+6,987	New	+$1.96M	1.78%	33

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hammer Asset Management's BIIB Position: Q2 2020 in Review

Hammer Asset Management sold out of Biogen (BIIB) in Q2 2020, closing a stake of 824 shares — an estimated $261K sold.

Hammer Asset Management first reported a position in BIIB in Q2 2018 and held it in 5 quarters. The position peaked at $2.03M in Q2 2018. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Hammer Asset Management reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
Hammer Asset Management sold 824 Biogen shares in Q2 2020, an estimated $261K.
Hammer Asset Management first reported a position in Biogen in Q2 2018 and held it in 5 quarters.
Hammer Asset Management's Biogen position peaked at $2.03M in Q2 2018.
1,059 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Hammer Asset Management's 13F filing for Q2 2020, filed 24 Jul 2020.